More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity or type 2 diabetes, researchers reported in San Francisco at ENDO 2025, the ...

Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

By Rishika Sadam HYDERABAD (Reuters) -Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters, ...

Biocon plans to launch generic copies of Wegovy in India and Canada within two years, targeting a growing drug market ...

MUNICH (Reuters) -German packaging and medical equipment maker Gerresheimer has ended discussions on a potential sale of the ...

More than half of large employers plan to scale back health care benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new survey released by ...

Temasek spent $2 billion in April 2023 to raise its stake in Manipal to 59% from 18% in the biggest hospital sector deal ever ...

Biocon is set to launch generic versions of Wegovy in India and Canada, aiming for market entry by late 2026 or early 2027.

Weight Watchers went bankrupt in May, but now it promises it's trimmed the fat off its books and is ready to rejoin the ...